Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343809 | 0.87 | TSHR (0.47) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4344053 | 0.86 | GAA (0.41) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4347315 | 0.86 | EGFR (0.49) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4346893 | 0.84 | PTGS1 (0.41) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4349759 | 0.80 | NPSR1 (0.43) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4353671 | 0.79 | P2RX1 (0.49) | RAB9AP2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL4346853 | 0.78 | STK39 (0.51) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4341696 | 0.77 | P2RX1 (0.54) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4342472 | 0.77 | P2RY1 (0.41) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL4353445 | 0.76 | TSHR (0.47) | MEN1MAPTRAB9AKMT2AP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | MEN1 3901/4885MAPT 4184/4885RAB9A 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.